Clinica Universidad De Navarra
- Address
- Calle Marquesado De Santa Marta 1, 28027 Madrid, Spain
Clinica Universidad De Navarra - Leading Oncology and Rare Disease Research Center
Clinica Universidad De Navarra is a distinguished academic medical center conducting cutting-edge clinical research across multiple therapeutic areas. The institution demonstrates particular expertise in advanced solid tumor malignancies and hematologic cancers, with extensive involvement in novel immunotherapy and targeted therapy development. Their research portfolio reflects a commitment to early-phase drug development and precision medicine approaches.
- Comprehensive oncology trials including advanced solid tumors, breast cancer, lung cancer, ovarian cancer, hepatocellular carcinoma, and colorectal cancer
- Hematologic malignancy research focusing on multiple myeloma, diffuse large B-cell lymphoma, follicular lymphoma, and other B-cell non-Hodgkin lymphomas
- Innovative immunotherapy combinations including bispecific antibodies, checkpoint inhibitors, and CAR-T cell engagers
- Specialized rare disease research in hypoparathyroidism and metabolic disorders including MASH (metabolic dysfunction-associated steatohepatitis)
The center maintains a robust research infrastructure supporting complex Phase 1/2 dose-escalation studies, randomized controlled trials, and window-of-opportunity designs. Their therapeutic investigations span from novel cancer vaccines and antibody-drug conjugates to precision oncology approaches targeting specific genetic alterations such as KRAS-G12C mutations and EGFR exon 20 insertions. The institution also conducts important studies in neurodegenerative diseases including Alzheimer's disease and dermatologic conditions like vitiligo and actinic keratosis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 96 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 96 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1Regeneron Pharmaceuticals Inc.4active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG6trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinica Universidad De Navarra
lock Showing 1 of 44 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 96 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 5 | Unknown | 2020-01-30 | 2024-02-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.